Bayview’s current performance at a glance*
* Based on current data
Turning data into action at Bayview: 70% of healthcare decisions involve lab results1
Our advanced diagnostics and analytics can help Bayview uncover high-impact opportunities that improve patient care and strengthen value-based results.
The National Kidney Foundation recommends screening patients with diabetes and hypertension using both uACR and eGFR—yet this combined testing is often missed.2
Of the testing Bayview sent to Quest in the past 12 months:
For higher-risk patients (eGFR <60 or uACR >30), 2024 KDIGO guidelines highlight using eGFR with creatinine + cystatin C for a more accurate assessment of kidney function and risk.³
Quest options to support CKD quality metrics and outcomes:
Research indicates that up to 30% of patients with hypertension have primary aldosteronism.⁴
In the past 12 months at Bayview:
- 33 patients had essential hypertension
- While up to 30% could have PA, 0 patients were screened
Screening can help identify patients at risk.
Metabolic dysfunction increases cardiovascular risk and total cost of care.
- A high TG/HDL-C ratio is associated with insulin resistance (IR), metabolic syndrome, and dyslipidemia indicated by elevated apolipoprotein B (ApoB)⁵
- IR affects more than 60 million Americans and can be detected up to 10 years before HbA1c reaches 5.6%—enabling earlier intervention⁶
- Guidelines highlight that ApoB more accurately predicts risk in patients with metabolic dysfunction, such as those with abnormal TG/HDL-C ratios5
In the past 12 months at Bayview:
- 47 patients had an abnormal TG/HDL-C ratio suggesting possible IR/dyslipidemia
- 28 had HbA1c 5.0%–5.6%, where IR assessment may be most impactful
Screening can help identify patients at risk for cardiometabolic disease, prediabetes, and diabetes.
An estimated 48% of adults have metabolic dysfunction–associated steatotic liver disease (MASLD), placing them at increased risk of progression to metabolic dysfunction–associated steatohepatitis (MASH) and related complications.7
About 20% of patients with MASLD progress to MASH, which is strongly linked to liver-related events such as cirrhosis, transplant, and death.7,8
In the past 12 months at Bayview:
- 21 patients had a FIB-4 score of 1.30-2.67
- 3 patients had a FIB-4 score >2.67
The Comprehensive Metabolic Panel with Fibrosis-4 (FIB-4) Index provides the FIB-4 score used to estimate liver fibrosis and identify patients at risk for advanced disease.
Guidelines recommend that indeterminate or high FIB-4 results be followed up with the Enhanced Liver Fibrosis (ELF) blood test.9 At Bayview, 24 patients may benefit from ELF testing.
Every data point tells part of the story—connecting insights drives better outcomes
With Quest data and analytics, Bayview can address patient populations across the risk continuum
Our analytics and clinical intelligence can help you identify gaps in care, manage risk across populations, and strengthen performance under value-based contracts.
Learn more about how we support organizations just like yours working towards value-based care.
Key VBC enablement takeaways for Bayview
Dedicated support
Kay Mansukhani
References
- CMS.gov. FDA and CMS statement: Americans deserve accurate and reliable diagnostic tests, wherever they are made. January 18, 2024. Accessed October 15, 2025. https://www.cms.gov/newsroom/press-releases/fda-and-cms-statement-americans-deserve-accurate-and-reliable-diagnostic-tests-wherever-they-are
- National Kidney Foundation. Laboratory engagement initiative (LEI). 2025. Accessed June 11, 2025. https://www.kidney.org/professionals/ckdintercept/laboratory-engagement-initiative-lei
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
- Marcelli M, Bi C, Funder JW, McPhaul MJ. Comparing ARR versus suppressed PRA as screening tests for primary aldosteronism. Hypertension. 2024;81(10):2072-2081. doi:10.1161/HYPERTENSIONAHA.124.22884
- Manapurath RM, Hadaye R, Gadapani B. Normal weight obesity: Role of apoB and insulin sensitivity in predicting future cardiovascular risk. Int J Prev Med. 2022;13:31. doi:10.4103/ijpvm.IJPVM_139_20
- Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018;2(9):1050-1057. doi:10.1210/js.2018-00107
- Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH): Updated estimates from 2000–2022. J Hepatol. 2023;79(5):1111-1120. doi:10.1016/j.jhep.2023.07.017
- Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. doi:10.1016/S2468-1253(22)00165-0
- Chalasani N, Younossi Z, Lavine JE, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000358
- KFF. How do healthcare expenditures vary across the population? January 5, 2024. Accessed August 20, 2024. https://www.kff.org/slideshow/how-health-expenditures-vary-across-the-population-slideshow
Test codes may vary by location. Please contact your local laboratory for more information.
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.